{{Rsnum
|rsid=13073869
|Gene=PPARG
|Chromosome=3
|position=12312494
|Orientation=plus
|GMAF=0.2686
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PPARG
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 5.3 | 36.3 | 58.4
| HCB | 15.3 | 40.1 | 44.5
| JPT | 10.7 | 33.9 | 55.4
| YRI | 4.8 | 30.8 | 64.4
| ASW | 3.5 | 43.9 | 52.6
| CHB | 15.3 | 40.1 | 44.5
| CHD | 13.0 | 44.4 | 42.6
| GIH | 4.0 | 37.4 | 58.6
| LWK | 3.7 | 33.0 | 63.3
| MEX | 17.2 | 48.3 | 34.5
| MKK | 11.5 | 40.4 | 48.1
| TSI | 5.0 | 38.6 | 56.4
| HapMapRevision=28
}}

Associated with risk of lung cancer in a Chinese population {{PMID|18187557}}

{{PMID|17213274|OA=1
}} Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}